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costs. In a health care system like Ontario’s, which treats 2800 new breast cancer 
patients per year, this may represent a signiﬁ cant reduction in operation cost. These
savings should be considered in context of how much resource investment is required
to reduce waiting.
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OBJECTIVES: Squamous cell carcinoma of the head and neck (SCCHN) can be a 
devasting disease. Cetuximab has recently been shown to improve locoregional control
(LRC) and reduce mortality in locally and regionally advanced disease. The objective
of the study is to estimate the incremental cost-utility of cetuximab plus radiotherapy 
(CxRT) versus cisplatin plus radiotherapy (CsRT) among platinum eligible patients
and versus RT alone in platinum ineligible patients in Canada. METHODS: A lifetime 
transition model was developed with four health states: 1) acute treatment phase; 2)
LRC; 3) disease progression and 4) death. Adverse events were accounted for in the
ﬁ rst two states. Efﬁ cacy of treatment (LRC and overall survival) was obtained from 
the literature. Based on network meta-analyses, CsRT and CxRT were assumed to
have equal efﬁ cacy. Resource use was obtained from published literature and clinical 
expert opinion. The perspective adopted was that of a provincial ministry of health
or cancer agency. Utilities were obtained from a previous study of UK oncology nurses.
Costs (CDN$2008) and outcomes were discounted at 5% annually. Incremental cost-
effectiveness ratios (ICERs) were reported with one-way and probabilistic sensitivity
analyses performed to assess robustness of results. A priori sub-group analyses were 
carried out by baseline Karnofsky Performance Scores (KPS). RESULTS: Among 
all patients (KPS 60–100), the ICERs comparing CxRT to RT were $19,740/QALY 
(95% CI: $11,122 to $695,295) among platinum ineligible patients and for CxRT vs. 
CsRT, $99,147/QALY (95% CI: $75,998 to $148,951) among platinum eligible 
patients. ICERs decreased with increasing KPS scores. At a willingness-to-pay of 
$50,000 among platinum-ineligible patients and $100,000 among platinum-eligible
patients, the likelihood that CxRT is cost-effective is 90% and 45% respectively. Sen-
sitivity analyses indicated that time horizon and assumptions about CsRT effectiveness
had the largest impact on results. CONCLUSIONS: Cetuximab is an economically
attractive option for SCCHN patients.
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OBJECTIVES: To determine incremental costs and life expectancy of adding bevaci-
zumab (bev) to an irinotecan plus infusional 5-ﬂ uorouracil/leucovorin (5-FU/LV) 
regimen (FOLFIRI) for the ﬁ rst-line treatment of patients with metastatic colorectal 
cancer (MCRC) in the UK. METHODS: We performed a decision analysis with a
THREE-health-state area under the curve model to explore the effects of adding bev 
treatment to an existing FOLFIRI-based regimen. The model structure was based on
a published model by National Institute of Technology Excellence (NICE), UK. Pro-
gression-free (PFS) and overall survival (OS) data were derived from clinical trials 
comparing bevirinotecan and 5-FU/LV (IFL) with IFL alone. The impact on OS for 
bevFOLFIRI was included through an indirect comparison of hazard ratios (HRs)
between bevmIFL versus bevFOLFIRI (HR for death: 1.79; 95% CI: 1.12–2.88).
Treatment effect for bevFOLFIRI was maintained during the 40-month clinical
follow-up. The FOLFIRI PFS was created by applying the HR from IFL versus
FOLFIRI (HR for progression or death: 1.51, 95% CI: 1.16–1.97) to the IFL PFS. 
Outcomes included life years, QALYs, direct costs and incremental cost-effectiveness 
ratios (ICERs). A life-time horizon (8 years) was used. Cost and outcomes were dis-
counted by 3.5% per annum. Both deterministic and probabilistic sensitivity analyses 
were performed. RESULTS: The estimated discounted life expectancy for bevFOLFIRI-
treated patients was 2.62 years (undiscounted: 2.77 years) versus 1.58 years (undis-
counted: 1.63 years) in the FOLFIRI arm. The discounted costs in the 2 arms were
a49,798 and a23,698, respectively. The discounted ICER was a25,045 per life-year
gained and a40,532 per QALY gained. Sensitivity analysis on key variables showed
that assumptions of size (HR) and duration of treatment effect were the most inﬂ u-
ential factors for the ICER. CONCLUSIONS: BevFOLFIRI versus current FOLFIRI-
based treatment regimens for MCRC increases survival for these patients and is a cost
effective treatment option.
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OBJECTIVES: To model expected mean incremental costs and life expectancy of 
adding bevacizumab (bev) to an irinotecan plus infusional 5-ﬂ uorouracil/leucovorin
(5-FU/LV) regimen (FOLFIRI) for the ﬁ rst-line treatment of patients with metastatic 
colorectal cancer (MCRC) in Sweden. METHODS: A 3-health-state model explored 
the effects of adding bev treatment to an existing FOLFIRI-based regimen. The model
structure was based on one published by National Institute for Health and Clinical
Excellence (NICE) UK, which applies to guidelines established by the Swedish Phar-
maceutical and Dental Beneﬁ ts Board. Progression-free (PFS) and overall survival (OS)
data are derived from clinical trials comparing bevirinotecan and 5-FU/LV (IFL) with 
IFL alone. The impact on OS for bevFOLFIRI was included through an indirect 
comparison of hazard ratios (HRs) between bevmIFL versus bevFOLFIRI (HR for 
death: 1.79; 95%CI: 1.12–2.88). Treatment effect for bevFOLFIRI was maintained
during the 40-month clinical follow-up. The FOLFIRI PFS was created by applying 
the HR from IFL versus FOLFIRI (HR for progression or death: 1.51, 95%CI: 1.16–
1.97) to the IFL PFS. Outcomes included life years, QALYs, direct costs and incre-
mental cost-effectiveness ratios (ICERs). A life-time horizon (eight years) was used.
Cost and outcomes were discounted by 3% per annum. RESULTS: The estimated 
mean life expectancy for bevFOLFIRI-treated patients was 2.64 years (discounted; 
2.77 years undiscounted) versus 1.58 years (discounted; 1.63 years undiscounted) in 
the FOLFIRI arm. The discounted costs in the 2 arms were 525,404 SEK and 245,775
SEK, respectively. The discounted ICER was 264,689 SEK/life-year gained and 
428,519 SEK/QALY gained. Sensitivity analysis on key variables showed that assump-
tions of size (HR) of treatment effect and duration of treatment effect were the most 
critical factors for the ICER. CONCLUSIONS: BevFOLFIRI versus current FOLFIRI-
based treatment regimens for MCRC is predicted to increase survival for these patients 
and also be a cost-effective treatment option in Sweden.
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OBJECTIVES: In EGF100151, lapatinib plus capecitabine (LC) improved time to 
progression (TTP) vs C-only (Median 27.1 vs 18.6 wks, HR  0.57, p  0.001) in 
women with ErbB2 MBC who had received prior CT with TZ, anthracyclines, and 
taxanes. In GBG26, TZ plus capecitabine (TZC) improved TTP vs C-only in ErbB2
MBC patients with prior TZ and a1 prior courses of palliative CT (n  74 vs 77, 
median 36.9 vs 24.3 wks, HR  0.69, p  0.034). Because 50% of EGF100151 
patients had received q4 prior lines of CT, results of EGF100151 and GBG26 are not 
directly comparable. The objective of this analysis was to evaluate (1) the CE (cost 
per quality-adjusted life year [QALY] gained) of TZC vs C-only in GBG26 and 
(2) the CE of LC vs C-only in a subgroup of comparable EGF100151 patients 
(3 CT, n  31 vs 37, TTP: Median 49.4 vs 19.7 wks, HR  0.37, p  0.0059, OS: 
Median 87.3 vs 55.1 wks, HR  0.51, p  0.0140). METHODS: Trial-based survival 
analyses were conducted of GBG26 patients and of EGF100151 patients with 3 CT, 
with progression-free survival (PFS) and OS for each treatment arm estimated by
ﬁ tting Weibull survival functions to failure-time data. A UK National Health Service 
perspective was employed. Costs and utilities were estimated using data from 
EGF100151 and the literature. RESULTS: The increase in QALYs for LC vs C-only 
among EGF100151 patients with 3 CT is 0.462; for TZC vs C-only in GBG26,
0.167. The increase in costs for LC vs C-only among EGF100151 patients with 3 
CT is a24,094; for TZC vs C-only in GBG26, a23,198. CE with LC vs C-only 
among EGF100151 patients with 3 CT is a52,152/QALY; for TZC vs C-only in 
GBG26, a138,910/QALY. CONCLUSIONS: In TZ-refractory ErbB2 MBC patients
with limited CT exposure, CE of LC vs C-only may be more favorable than CE of 
TZC vs C-only.
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COST-UTILITY ANALYSIS OF GEFITINIB VERSUS DOCETAXEL IN A
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OBJECTIVES: Calculate life expectancy and quality of life of geﬁ tinib versus docetaxel 
in the treatment of non-small-cell lung cancer in a Mexican public institution (ISSSTE).
METHODS: A Discrete Event Simulation model was designed to emulate probabilities 
of having one or more adverse events at the same time when in treatment for
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non-small-cell lung cancer (NSCLC) using geﬁ tinib or docetaxel. Probability distribu-
tions for adverse events and life expectancy were obtained from the INTEREST
study. We used a docetaxel chemotherapy cost-study at ISSSTE and for geﬁ tinib 
we used the drug’s institutional price. Health state utility values for calculating
QALYs (Quality Adjusted Life Years) were derived from a recently published study
done with UK patients. A 3% annual discount rate was applied on a monthly basis
to all costs. Finally, a probabilistic sensitivity analysis was made varying the cost of 
chemotherapy. The model was run 25 times with 500 patients in each arm. Results
are presented in US dollars with an exchange rate of 13.5 MXN pesos for 1 US dollar. 
RESULTS: There was no clinical difference in life expectancy between geﬁ tinib (10.25
months) and docetaxel (10.14 months). Average QALY for geﬁ tinib cohort was 0.487 
(95% CI, 0.437 – 0.537) and for chemotherapy cohort was 0.438 (95% CI, 0.388 –
0.488). The average cost per patient treated with geﬁ tinib was $12,103 (95% CI, 
$11,916 – $12,290) and with docetaxel was $20,076 (95% CI, $19,866 – $20,286).
The acceptability curve shows a 100% dominace of geﬁ tinib over docetaxel, after a
chemotherapy price of $1,333. CONCLUSIONS: Geﬁ tinib is an alternative therapy 
for second line treatment of NSCLC that dominates docetaxel chemotherapy, in terms 
of quality of life related to reduced presence of adverse events, at a lesser cost to the 
institution.
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OBJECTIVES: Chronic myelogenous leukaemia (CML) is a progressive disease associ-
ated with a signiﬁ cant burden on both the patient and the health care provider. 
Although durable response from imatinib is achievable for many patients, some
develop resistance or intolerance. In these patients, other tyrosine kinase inhibitors 
(TKIs), such as dasatinib and nilotinib are treatment options. This study uses outputs
from recent clinical trials evaluating TKIs to predict the long-term economic and cost 
outcomes associated with different levels of best response. METHODS: A Markov
model was developed to estimate the costs and health outcomes associated with 
chronic, accelerated and blast phase CML. Short-term response was deﬁ ned as ‘no
response’ (NR), ‘complete haematological response’ (CHR), partial cytogenetic
response (PCR) and complete cytogenetic response (CCR). Resource use and quality-
adjusted life year (QALY) scores were stratiﬁ ed according to the patient’s current 
health status and response level. RESULTS: Patients in the chronic phase who achieve 
no response are estimated to experience a total of 1.50 QALYs and incur costs of 
a57,867 over their lifetime. Those who achieve CHR, PCR and CCR experience 3.47,
7.31 and 10.17 QALYs, and costs of a62,617, a66,499 and a67,117 respectively. In
the accelerated phase, the total number of QALYs for the NR, CHR, PCR and CCR
groups were 0.71, 1.70, 1.57 and 4.10 respectively. For the same groups, the lifetime 
costs were a35,273, a35,850, a35,886 and a51,693. In the blast phase, the QALY 
outcomes for the four groups were 0.18, 0.41, 0.63 and 1.46, whilst the costs were 
a13,252, a7,109, a10,993 and a25,501 respectively. CONCLUSIONS: There is a 
strong apparent relationship between short-term response to treatment and long-
term outcomes in CML. These ﬁ ndings are likely to be useful in assessing the cost-
effectiveness of existing treatments, whose short-term response is known, but where 
long-term data are currently unavailable.
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OBJECTIVES: To estimate the cost effectiveness of Posaconazole versus ﬂ uconazole/
itraconazole therapy in the prophylaxis against invasive fungal Infections among high-
risk neutropenic patients in Mexico. METHODS: A previously validated Markov
model was used to compare the projected lifetime costs and effects of two theoretical 
groups of patients, one receiving Posaconazol and the other receiving ﬂ uconazole/itra-
conazole. The model estimates total costs, numbers of IFIs, and QALY per patient in
each prophylaxis group. The model was extended with one-month Markov cycles in
which mortality risk is speciﬁ c to the underlying disease. Data on the probabilities of 
IFI were obtained from Study Protocol PO1899. Drug costs were taken from average 
wholesale drug reports for 2008. Cost and health effects were discounted at 5%. The
analysis was conducted from the Mexican health care perspective using 2008 unit cost
prices. RESULTS: Our model projects an accumulated cost to the Mexican health care
system per patient receiving the Posaconazol regimen of US$7463 compared to 
US$5634 for the ﬂ uconazole/itraconazole regimen. This results in an incremental cost
of –(US$1829) per patient. The accumulated discounted effect is 3.13 life years or 
2.25 quality adjusted life years (QALYs) per patient receiving Posaconazol, compared 
to 3.13 life years or 2.13 QALYs per patient receiving ﬂ uconazole/itraconazol. This 
translates into an incremental effect of posaconazole over ﬂ uconazole/itraconazole of 
0.17 life years gained (LYG) or 0.12 QALYs gained. The corresponding incremental 
cost effectiveness ratio (iCERs) is -(US$15,125) per QALY. Probabilistic sensitivity 
analysis tested numerous assumptions about the model cost and efﬁ cacy parameters
and found that the results were robust to most changes. CONCLUSIONS: The use of 
temozolomide in place of ﬂ uconazole/itraconazole for the prophylaxis against invasive
fungal Infections among high-risk neutropenic patients is likely to be cost saving. 
These conclusions are supported by the use of conservative assumptions and sensitivity 
analyses.
PCN75
THE IMPACT OF NEUTROPENIC COMPLICATIONS ON SHORT-TERM
DISABILITY IN PATIENTS WITH CANCER RECEIVING CHEMOTHERAPY
Song X1, Fowler R2, McGufﬁ e K2, Hurley D3, Barron RL3
1Thomson Reuters, Cambridge, MA, USA, 2Thomson Reuters, Washington, DC, USA, 
3Amgen, Inc., Thousand Oaks, CA, USA
OBJECTIVES: Patients receiving myelosuppressive chemotherapy are at risk for che-
motherapy-induced neutropenic complications (CINC). The study objective was to
examine the impact of CINC, deﬁ ned as neutropenia with fever or infection, on short-
term disability (STD) among cancer patients receiving chemotherapy. METHODS:
Patients with cancer undergoing chemotherapy were extracted from Thomson Reuters
MarketScan Commercial Database and Health and Productivity Management Data-
base. Patients were required to have at least 6 months continuous enrollment before 
the index date (ﬁ rst chemotherapy claim) and at least 30 days continuous enrollment
post-index date, full-time employment and eligibility for STD. Patients with ICD-9
codes for neutropenia and fever or infection and that had evidence of chemotherapy 
within 30 days prior were deﬁ ned as having CINC. Propensity score (PS) matching
was conducted for “CINC” and “non-CINC” patients based on demographic and
clinical characteristics, including chemotherapy class and use of highly myelosuppres-
sive chemotherapeutic agents. Subsequent multivariate regressions were conducted on
PS-matched cohorts to estimate the marginal impact of CINC: an Ordinary Least 
Squares Model on STD days, a generalized linear model on indirect cost associated 
with STD, and a logistic regression model on whether a patient used any STD days
during a month. RESULTS: A total of 280 CINC and 280 non-CINC patients were
PS-matched. Compared with matched non-CINC patients, CINC patients on average 
experienced 0.9 more STD day (3.2 vs. 2.3, p  0.046) which led to $156 more in
indirect costs ($549 vs. $394, p  0.050) per month. After multivariate adjustment,
CINC patients were 35% (p  0.121) more likely to experience at least one STD day,
experienced 1.0 more STD day (p  0.029), and incurred $200 more in indirect cost 
(p  0.016) per month. CONCLUSIONS: Patients with CINC experience signiﬁ cantly 
greater STD days than patients with no neutropenic complications from cancer che-
motherapy. Efforts that may prevent CINC can potentially have a beneﬁ cial impact 
on work absenteeism.
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OBJECTIVES: The accident at the Chernobyl nuclear power plant in 1986 released 
an enormous amount of radioactive materials which spread over the territories of 
Ukraine, Belarus, Russia and other European countries. The damage caused to the
environment, economy and, most importantly, to human health has been challenging 
to estimate. In fact, there is no scientiﬁ c agreement on the severity of the Chernobyl
aftermath. The purpose of our paper is to investigate the long-run impact of the
tragedy on the labor market outcomes of the Ukrainian population. METHODS:
Speciﬁ cally, using data from 2001 household survey and a self-reported measure of 
well-being, we estimate the impact of the Chernobyl accident on individual earnings. 
In addition, we identify a substantial gender wage gap existing in the Ukrainian labor 
markets. We use the Oaxaca decomposition technique to examine the wage gap in 
more detail. RESULTS: We ﬁ nd that those individuals whose health has suffered as a
result of the accident receive on average 5% lower wages, after controlling for other 
characteristics. CONCLUSIONS: We ﬁ nd that a large portion of the wage gap is 
“unexplained” and may be attributed to discrimination against women; in addition,
the health effects of the Chernobyl accident explain a signiﬁ cant portion of the gender 
wage inequality.
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OBJECTIVES: After initial therapy with imatinib, chronic myelogenous leukemia 
(CML) patients who do not completely respond may require dose escalation or switch-
ing to another BCR/ABL kinase inhibitor to achieve the desired response. This study 
compared health care resource utilization associated with either escalation of imatinib 
dose or switching to dasatinib. METHODS: Two large administrative claims databases 
were combined (MarketScan and Ingenix Impact, January 1999–March 2008) to 
identify patients diagnosed with CML (ICD-9 code: 205.1). Patients initiated with 
imatinib who were continuously enrolled 6 months prior to and at least one month 
following their ﬁ rst dose increase or switch to dasatinib were selected. Patients who
switched to dasatinib before reaching imatinib 800 mg/day (switchers) and the non-
